


Hypopituitarism in Wilson's disease resolved after copper-chelating therapy

Nina Dauth¹ , Victoria T Mücke², Marcus M Mücke², Christian M Lange³,
Martin Welker², Stefan Zeuzem² and Klaus Badenhoop²

¹MVZ Diamedicum Würzburg GmbH, Würzburg, Germany, ²Medical Department 1, University Hospital of the Goethe-University Frankfurt, Frankfurt am Main, Germany, and ³Clinic for Gastroenterology and Hepatology, University Hospital Essen and University Duisburg-Essen, Essen, Germany

Correspondence
should be addressed
to N Dauth
Email
dauth@diamedicum.de

Summary

Wilson's disease (WD) is a rare disorder of copper metabolism usually presenting with variable liver damage and neuropsychiatric symptoms. Here we report a 39-year-old Taiwanese female with late manifestation of WD presenting with gonadotroph, thyrotroph and corticotroph hypopituitarism. Molecular genetic testing revealed compound heterozygosity for two mutations in exons 12 and 14 (c.2828G>A and c.3140A>T). Copper-chelating therapy with D-penicillamine and zinc was initiated along with supplementation of hydrocortisone and L-thyroxine. Hypopituitarism resolved when urinary copper excretion returned to normal levels under copper chelation. This case should raise awareness of pituitary function in WD patients.

Learning points:

- Hypopituitarism can complicate Wilson's disease (WD) and endocrinologists should be aware of it when caring for hypopituitary patients.
- Hepatologists should consider endocrinologic testing for hypopituitarism when WD patients present with symptoms of adrenal insufficiency, thyroid or gonadal dysfunction.
- Copper-chelating treatment is mandatory and may lead to the recovery of pituitary function in such patients.

Background

Wilson's disease (WD) is a monogenic copper disorder associated with liver failure and progressive lenticular degeneration. Especially in younger patients, the initial manifestation goes along with acute fulminant liver failure, followed by liver transplantation due to high-urgency registration for organ transplant. Hypopituitarism is an exceedingly rare and unusual complication of WD but must be kept in mind when dealing with WD patients especially when unusual symptoms such as hypoglycemia or amenorrhea occur. Diagnosis of hypopituitarism can be challenging since many patients may be asymptomatic or symptoms may be accredited to the underlying liver disease. When hypopituitarism is confirmed, hormone

replacement is mandatory according to the extent of pituitary insufficiency. While hypopituitarism is usually irreversible, copper-chelating treatment can facilitate hormonal recovery in WD.

Case presentation

Introduction

Wilson's disease (WD) is a rare monogenetic disorder in which excess copper is deposited mainly in parenchymal organs such as liver and brain. Liver cirrhosis is the most severe complication and often the first obvious clinical manifestation of the disease. Excessive copper

accumulation may lead to hepatic and/or neuropsychiatric symptoms and to complex biochemical changes (1, 2). The recessive disease is due to mutations in the ATPase copper transporting beta polypeptide (ATP7B) gene on chromosome 13 (3). Diagnosed and treated at young age, WD has a favorable prognosis (4), but phenotypes are heterogeneous and may be late- or misdiagnosed (5).

With WD itself being a challenging diagnosis to the treating physician, hormonal dysfunction due to copper accumulation in endocrine glands rarely occurs and causes various symptoms that need precise interpretation followed by appropriate treatment.

Here we report a case with late-diagnosed WD and endocrine dysfunctions that resolved after copper chelation.

Case presentation

A 39-year-old Taiwanese female presented with jaundice, nausea, fatigue and writer's cramps that had evolved within few days without any triggering events. The medical history was unremarkable with two normal deliveries and healthy children without any specific family history. The patient had no siblings. The patient did not consume alcohol, used to drink green tea regularly (four to six cups per week), was on a vegan diet and used a hormonally active contraceptive coil (Levonorgestrel, Mirena®) for approximately 3 years. No over the counter supplements, herbs or creams were used.

On examination she was jaundiced but had otherwise normal vital signs, the routine laboratory results are presented in Table 1. Abdominal ultrasound showed a compensated liver cirrhosis with portal hypertension and splenomegaly. A transcutaneous liver biopsy revealed no evidence for a nutritive toxic liver damage and other common hepatopathies. Hepatic parenchymal copper concentration revealed a high hepatic copper content of 1338 mg/kg (normal range: 10–35 mg/kg). In addition, the serum ceruloplasmin was low (10.7 mg/dL, normal range: 25–60 mg/dL), the 24-h urinary copper excretion was increased with 708 µg per day (normal range: 10–60 µg/day) and a coombs-negative hemolytic anemia was present (hemoglobin: 10.2 mg/dL; lactate dehydrogenase (LDH): 385 U/L). Thus, the diagnosis of Wilson's disease had to be made.

T2 MRI visualized increased densities in basal ganglia with the characteristic 'face of the giant panda' sign (Fig. 1). Genetic testing of the ATP7B gene revealed two heterozygous mutations: c.3140A>T (p.Asp1047Val) on exon 14 and c.2828G>A (p.Gly943Asp) in exon 12

Table 1 Baseline laboratory and copper parameters.

Parameter	Value	Reference values
Sodium, mmol/L	136	135–145
Potassium, mmol/L	3.6	3.6–4.8
Creatinine, mg/dL	0.7	0.5–0.9
Albumin, g/dL	2.7	3.5–5.2
Bilirubin, ng/dL	0.7	<0.9
Alanine transferase, U/L	86	<35
Gamma-glutamyltransferase, U/L	211	<40
Alkaline Phosphatase, U/L	54	55–105
Lactate dehydrogenase, U/L	385	<248
Leukocytes, /nL	4.07	3.96–10.41
Erythrocytes, /pL	2.75	3.96–5.16
Hemoglobin, g/dL	10.2	11.6–15.5
Hematocrit, %	31.1	34.6–45.3
Thrombocytes, /nL	93	176–391
Prothrombin time, %	41	70–130
International normalized ratio	1.90	
Hepatic copper content, mg/kg	1338	10–35
Ceruloplasmin, mg/dL	10.7	25–60
24-hour urinary copper excretion, µg/day	708	10–60
24-hour urinary copper excretion after 6 months, µg/day	60	10–60

which were classified as pathogenic variants (class V) of the ACMG-AMP system (6). Both are missense variants, have separately been described as WD causing variants (HGMD Professional 2017.1) and are localized in the




Figure 1 T2 magnetic resonance imaging (MRI) visualized increased densities in basal ganglia with the characteristic 'face of the giant panda'.




Figure 2

A subcutaneous continuous glucose monitoring (Dexcom G5 Mobile CGMS) revealed multiple hypoglycemic episodes but also transient hyperglycemia up to >200 mg/dL.

cation-transporting P-type ATPase domain. Although the variants are assumed to exist in trans, this needs to be confirmed by family testing.

Copper-chelation treatment was initiated by up titrating D-penicillamine and zinc with pyridoxine supplementation since penicillamine is known to inactivate pyridoxine. She was educated on medication compliance and stayed on a low-copper diet. She was also advised to quit the consumption of green tea since it is known to contain a high amount of copper. At this point, the patient had a stable disease with a Model for End-Stage Liver Disease (MELD) score of 15 obviating liver transplant considerations. The patient was evaluated for liver transplantation but not registered because of improving her state after initiation of copper depleting therapy.

On follow-up, she reported fatigue and amenorrhea since the levonorgestrel containing coil had been removed around 3 months before. Additionally, she complained of meal-independent hypoglycemic symptoms, which were confirmed by blood glucose self-monitoring. After dietary adjustments, hypoglycemia as low as 50 mg/dL were confirmed on hospital admission. A subcutaneous continuous glucose monitoring (Dexcom G5 Mobile rtCGM) (Fig. 2) revealed multiple hypoglycemic episodes but also transient hyperglycemia up to >200 mg/dL.

Adrenal dysfunction was found explaining hypoglycemia: low baseline cortisol (2.5 µg/dL, normal range: 6.24–18.0 µg/dL) and adrenocorticotropic hormone

(ACTH) (7.5 pg/mL, normal range: 7.2–63.6 pg/mL) confirmed by testing with 250 µg cosyntropin. Cortisol rose to a subnormal peak after 60 min (basal: 3.1 µg/dL, stimulated: 16.0 µg/dL, normal range: > 18 µg/dL) and adrenocorticotroph deficiency was diagnosed (Table 2).

In addition, she had thyrotroph insufficiency whereas the somatotroph function was not impaired. With decreased levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and estradiol we suspected gonadotroph insufficiency causing amenorrhea (Table 3).

Hypopituitarism was diagnosed involving the deficiency of the adrenocorticotroph, gonadotroph and thyrotroph axes. A sellar MRI ruled out pituitary adenoma but failed to show copper accumulation within the pituitary.

An oral glucose tolerance test was performed over 4.5 h with 75 g glucose to confirm diabetes mellitus and to rule out reactive postprandial hypoglycemia. Fasting glucose was normal, 2 h after oral glucose load it rose to 219 mg/dL and decreased to 61 mg/dL after 4.5 h with the patient showing hypoglycemic symptoms.

Substitution with hydrocortisone was started (10 mg/day), followed by L-thyroxine 50 µg/day and copper-chelating treatment continued. Within the following months, the patient's general condition improved considerably, and she did not observe any further hypoglycemia on glucose self-monitoring.

During follow-up, urinary copper excretion decreased to near-normal levels (<60 µg/day) and after 6 months



Table 2 Results from the cosyntropin stimulation test (normal peak >18 µg/dL after 60 min).

Parameter	Baseline	After 60 min
Cortisol, µg/dL	2.5	16
Cortisol after copper-chelating treatment, µg/dL	11.0	31

she reported menstrual cycles. The general condition further improved to full physical and mental fitness. After 48-h hydrocortisone cessation, another 250 µg cosyntropin stimulation test was performed and revealed a normal cortisol peak (basal 11 µg/dL, stimulated 31.0 µg/dL, normal range >18 µg/dL). Thyrotroph function normalized as well with TSH and free thyroid hormones being within the normal range. Substitution of hydrocortisone and L-thyroxine was discontinued and well-tolerated with normalized glycemia.

Taken together hypopituitarism with hypoglycemia resulted from copper accumulation presumably in the pituitary or its regulating ganglia, since copper-chelating treatment normalized pituitary function.

Investigation

Tables 1 and 3 present the various tests carried out.

Treatment

Copper-chelating treatment for Wilson's disease:

D-penicillamine 600 mg b.i.d.

Zinc 100 mg q.d.

Vitamin B₆ supplement

Pyridoxine 40 mg q.d.

Endocrine treatment for hypopituitarism:

L-thyroxine 50 µg q.d.

Hydrocortisone 5 mg b.i.d.

Outcome and follow-up

Six months after initiation of copper-chelating therapy, urinary copper excretion decreased to near-normal levels of less than 60 µg per day. By that time, the patient reported the return of regular menstruation cycles. Adrenal testing was normal and pituitary hormone levels also returned to normal indicating recovery of pituitary function. Subsequently, endocrine treatment was stopped. Genetic testing of the patient's children was recommended but not yet performed.

Discussion

Hypopituitarism with variable extent of endocrine dysfunction is a rare complication of WD. The underlying mechanism of hypopituitarism in WD remains elusive but pituitary copper deposition is most likely involved. Earlier serial studies in human WD described amenorrhea (7) and gonadotrophic dysfunction in males (8) that were put down to copper accumulation in the hypophysis. In addition, two case reports of young female WD patients illustrate signs and symptoms of pituitary dysfunction (9, 10). Previous reports of Asian patients also found pituitary dysfunction as part of WD in a Korean and a Chinese patient (11, 12) where one ATP7B mutation was shared with our case in the latter report. Taken together, we assume secondary neural damage to be the most likely cause of hypopituitarism in WD, but further research is needed to clarify this.

Our patient had symptomatic hypoglycemia as initial and typical manifestation of secondary adrenal

Table 3 Endocrine laboratory parameters before and after copper-chelating treatment.

Parameter	Initial value	Post-treatment	Reference values
Baseline cortisol, µg/dL	2.5	11.0	6.24–18
ACTH, pg/mL	7.5	8.4	7.2–63.6
TSH, mU/L	2.0	2.4	0.27–4.2
ft3, pg/mL	2.1	2.6	2.21–4.43
ft4, ng/dL	0.7	1.0	0.82–1.77
Insulin-like growth factor 1, ng/mL	121	107	106–256
LH, IU/L	5.3	3.5	2 – 10
FSH, IU/L	7.6	5.4	4 – 9
Estradiol, pg/mL	39	66	45 – 95
Prolactin, ng/mL	16.2		6.0 – 29.9
Insulin autoantibodies	Negative		
Insulin/Glucose ratio during hypoglycemia	< 0.3		



insufficiency, but also high glucose levels confirmed by 75 g oral glucose testing and continuous blood glucose monitoring. Another young female with WD also had presented with hypoglycemic insulin dysregulation (10). Since WD results from copper deposits in various tissues, an endocrine pancreas dysfunction may ensue and complement hepatic insulin resistance (13, 14, 15). In our patient diabetes was no longer detectable after copper chelation.

In conclusion, this case illustrates an association between endocrine dysfunction and WD. Physicians need to be alert since patients with WD can be oligosymptomatic. Copper-chelating treatment may lead to endocrine recovery. Vice versa WD should be considered as a possible cause of idiopathic hypopituitarism.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement

N D and M W were the patients' named physicians. N D, V T M, M M and M W contributed to acquisition of data, analysis and interpretation of data. N D, V T M and K B drafted the article. C L and S Z contributed to the discussion and revised the manuscript for content.

References

- 1 Frommer DJ. Defective biliary excretion of copper in Wilson's disease. *Gut* 1974 **15** 125–129. (<https://doi.org/10.1136/gut.15.2.125>)
- 2 Chowrimootoo GF, Ahmed HA & Seymour CA. New insights into the pathogenesis of copper toxicosis in Wilson's disease: evidence for copper incorporation and defective canalicular transport of caeruloplasmin. *Biochemical Journal* 1996 **315** 851–855. (<https://doi.org/10.1042/bj3150851>)
- 3 Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. *Human Genetics* 2006 **120** 151–159. (<https://doi.org/10.1007/s00439-006-0202-5>)
- 4 Bruha R, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P, Nevoral J, Petryl J, Urbanek P, Jiraskova A, *et al.* Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. *Liver International* 2011 **31** 83–91. (<https://doi.org/10.1111/j.1478-3231.2010.02354.x>)
- 5 Trocello JM, Broussolle E, Girardot-Tinant N, Pelosse M, Lachaux A, Lloyd C & Woimant F. Wilson's disease, 100 years later. *Revue neurologique* 2013 **169** 936–943. (<https://doi.org/10.1016/j.neurol.2013.05.002>)
- 6 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine* 2015 **17** 405–424. (<https://doi.org/10.1038/gim.2015.30>)
- 7 Kim JM, Ko SB, Kwon SJ, Kim HJ, Han MK, Kim DW, Cho SS & Jeon BS. Ferrous and ferric iron accumulates in the brain of aged Long-Evans Cinnamon rats, an animal model of Wilson's disease. *Neuroscience Letters* 2005 **382** 143–147. (<https://doi.org/10.1016/j.neulet.2005.03.003>)
- 8 Quemeneur AS, Trocello JM, Ea HK, Ostertag A, Leyendecker A, Duclos-Vallée JC, de Vernejoul MC, Woimant F & Lioté F. Bone status and fractures in 85 adults with Wilson's disease. *Osteoporosis International* 2014 **25** 2573–2580. (<https://doi.org/10.1007/s00198-014-2806-2>)
- 9 Frydman M, Kauschansky A, Bonne-Tamir B, Nassar F & Homburg R. Assessment of the hypothalamic-pituitary-testicular function in male patients with Wilson's disease. *Journal of Andrology* 1991 **12** 180–184.
- 10 Erkan T, Aktuglu C, Gulcan EM, Kutlu T, Cullu F, Apak H & Tümay GT. Wilson disease manifested primarily as amenorrhea and accompanying thrombocytopenia. *Journal of Adolescent Health* 2002 **31** 378–380. ([https://doi.org/10.1016/s1054-139x\(02\)00355-5](https://doi.org/10.1016/s1054-139x(02)00355-5))
- 11 Krysiak R, Handzlik-Orlik G & Okopien B. Endocrine symptoms as the initial manifestation of Wilson's disease. *Yale Journal of Biology and Medicine* 2012 **85** 249–254.
- 12 Lee HW, Kang JD, Yeo CW, Yoon SW, Lee KJ & Choi MK. Hypopituitarism presenting as adrenal insufficiency and hypothyroidism in a patient with Wilson's disease: a case report. *Journal of Korean Medical Science* 2016 **31** 1345–1348. (<https://doi.org/10.3346/jkms.2016.31.8.1345>)
- 13 Zhang QJ, Xu LQ, Wang C, Hu W, Wang N & Chen WJ. Four-year follow-up of a Wilson disease pedigree complicated with epilepsy and hypopituitarism: case report with a literature review. *Medicine* 2016 **95** e5331. (<https://doi.org/10.1097/MD.0000000000005331>)
- 14 Sulochana G & Viswanathan J. Wilson's disease with associated diabetes mellitus presenting as renal tubular acidosis. *Journal of the Association of Physicians of India* 1982 **30** 405–407.
- 15 Baig NA, Herrine SK & Rubin R. Liver disease and diabetes mellitus. *Clinics in Laboratory Medicine* 2001 **21** 193–207.

Received in final form 14 September 2020

Accepted 8 October 2020